Equity Research, Broker Reports, and media content on Summit Therapeutics

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Summit Therapeutics
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Summit Therapeutics. We currently have 108 research reports from 3 professional analysts.

Open
N/A
Range Today
N/A
52 Week
17.5/37.5p
Daily Volume
N/A
# Shares
160.5m
Daily Liquidity
(0.01%)
Pension Liability
£0m
Enterprise Value
£12.1m
Market Cap
£32.1m
Latest PE (hist)
Div Yield
Date Source Announcement
29Aug18 12:00 GNW Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
16Aug18 12:00 GNW Summit Awarded Additional $12 Million by BARDA for Ridinilazole
06Aug18 12:00 GNW Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
03Aug18 07:00 GNW Phase 2 Clinical Data Published Showing Summit's Ridinilazole Preserved Gut Microbiome of Patients with CDI
19Jul18 07:00 GNW Summit Therapeutics plc : Director/PDMR Shareholding
17Jul18 07:00 GNW Summit Therapeutics plc : Director/PDMR Shareholding
16Jul18 07:00 GNW Summit Therapeutics plc : Director/PDMR Shareholding
  • Frequency of research reports

     

  • Research reports on

    Summit Therapeutics

  • Providers covering

    Summit Therapeutics